Comparison and combination of blood-based inflammatory markers with faecal occult blood tests for non-invasive colorectal cancer screening

British Journal of Cancer

Volumn 106, Issue 8, 2012, Pages 1424-1430

  Tao, S ^a   Haug, U ^a   Kuhn, K ^a   Brenner, H ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

colorectal cancer screening; faecal occult blood tests; inflammatory markers

Indexed keywords

ANAPHYLATOXIN; C REACTIVE PROTEIN; COMPLEMENT COMPONENT C3A; DIPEPTIDYL PEPTIDASE IV; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ADENOMA; ADULT; AGED; ARTICLE; CANCER SCREENING; COLORECTAL CANCER; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NON INVASIVE MEASUREMENT; OCCULT BLOOD TEST; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY;

AGED; C-REACTIVE PROTEIN; COLORECTAL NEOPLASMS; DIPEPTIDYL PEPTIDASE 4; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOCHEMISTRY; INFLAMMATION; MALE; MASS SCREENING; MIDDLE AGED; OCCULT BLOOD; SENSITIVITY AND SPECIFICITY; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TUMOR MARKERS, BIOLOGICAL;

EID: 84859631722     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2012.104     Document Type: Article

References (28)

1. Brenner H, Chang-Claude J, Seiler CM, Rickert A, Hoffmeister M (2011) Protection from colorectal cancer after colonoscopy: a population-based, case-control study. Ann Intern Med 154: 22-30
2. Brenner H, Chang-Claude J, Seiler CM, Sturmer T, Hoffmeister M (2006) Does a negative screening colonoscopy ever need to be repeated? Gut 55: 1145-1150 (Pubitemid 44085683)
3. Brenner H, Chang-Claude J, Seiler CM, Sturmer T, Hoffmeister M (2007) Case-control study supports extension of surveillance interval after colonoscopicpolypectomy to at least 5 yr. Am J Gastroenterol 102: 1739-1744 (Pubitemid 47206678)
4. Brenner H, Haug U, Hundt S (2010a) Inter-test agreement and quantitative cross-validation of immunochromatographicalfecal occult blood tests. Int J Cancer 127: 1643-1649
5. Brenner H, Haug U, Hundt S (2010b) Sex differences in performance of fecal occult blood testing. Am J Gastroenterol 105: 2457-2464
6. Brenner H, Tao S, Haug U (2010c) Low-dose aspirin use and performance of immunochemical fecal occult blood tests. JAMA 304: 2513-2520
7. Cordero OJ, Ayude D, Nogueira M, Rodriguez-Berrocal FJ, de la Cadena MP (2000) Preoperative serum CD26 levels: diagnostic efficiency and predictive value for colorectal cancer. Br J Cancer 83: 1139-1146
8. De Chiara L, Rodriguez-Pineiro AM, Rodriguez-Berrocal FJ, Cordero OJ, Martinez-Ares D, Paez de la Cadena M (2010) Serum CD26 is related to histopathological polyp traits and behaves as a marker for colorectal cancer and advanced adenomas. BMC Cancer 10: 333
9. DeLong ER, DeLong DM, Clarke-Pearson DL (1988) Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 44: 837-845
10. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM (2008) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127: 2893-2917
11. Guittet L, Bouvier V, Mariotte N, Vallee JP, Arsene D, Boutreux S, Tichet J, Launoy G (2007) Comparison of a guaiac based and an immunochemical faecal occult blood test in screening for colorectal cancer in a general average risk population. Gut 56: 210-214
12. Habermann JK, Roblick UJ, Luke BT, Prieto DA, Finlay WJ, Podust VN, Roman JM, Oevermann E, Schiedeck T, Homann N, Duchrow M, Conrads TP, Veenstra TD, Burt SK, Bruch HP, Auer G, Ried T (2006) Increased serum levels of complement C3a anaphylatoxin indicate the presence of colorectal tumors. Gastroenterology 131: 1020-1029 (Pubitemid 44498688)
13. Haug U, Hundt S, Brenner H (2010) Quantitative immunochemical fecal occult blood testing for colorectal adenoma detection: evaluation in the target population of screening and comparison with qualitative tests. Am J Gastroenterol 105: 682-690
14. Hewitson P, Glasziou P, Watson E, Towler B, Irwig L (2008) Cochrane systematic review of colorectal cancer screening using the fecal occult blood test (hemoccult): an update. Am J Gastroenterol 103: 1541-1549 (Pubitemid 351813919)
15. Hol L, Wilschut JA, van Ballegooijen M, van Vuuren AJ, van der Valk H, Reijerink JC, van der Togt AC, Kuipers EJ, Habbema JD, van Leerdam ME (2009) Screening for colorectal cancer: random comparison of guaiac and immunochemical faecal occult blood testing at different cut-off levels. Br J Cancer 100: 1103-1110
16. Holten-Andersen MN, Christensen IJ, Nielsen HJ, Stephens RW, Jensen V, Nielsen OH, Sorensen S, Overgaard J, Lilja H, Harris A, Murphy G, Brunner N (2002) Total levels of tissue inhibitor of metalloproteinases 1 in plasma yield high diagnostic sensitivity and specificity in patients with colon cancer. Clin Cancer Res 8: 156-164 (Pubitemid 34101472)
17. Holten-Andersen MN, Fenger C, Nielsen HJ, Rasmussen AS, Christensen IJ, Brunner N, Kronborg O (2004) Plasma TIMP-1 in patients with colorectal adenomas: a prospective study. Eur J Cancer 40: 2159-2164 (Pubitemid 39165551)
18. Holten-Andersen MN, Murphy G, Nielsen HJ, Pedersen AN, Christensen IJ, Hoyer-Hansen G, Brunner N, Stephens RW (1999) Quantitation of TIMP-1 in plasma of healthy blood donors and patients with advanced cancer. Br J Cancer 80: 495-503 (Pubitemid 29213206)
19. Hundt S, Haug U, Brenner H (2007) Blood markers for early detection of colorectal cancer: a systematic review. Cancer Epidemiol Biomarkers Prev 16: 1935-1953 (Pubitemid 47621167)
20. Hundt S, Haug U, Brenner H (2009) Comparative evaluation of immunochemical fecal occult blood tests for colorectal adenoma detection. Ann Intern Med 150: 162-169
21. Kwon KA, Kim SH, Oh SY, Lee S, Han JY, Kim KH, Goh RY, Choi HJ, Park KJ, Roh MS, Kim HJ, Kwon HC, Lee JH (2010) Clinical significance of preoperative serum vascular endothelial growth factor, interleukin-6, and C-reactive protein level in colorectal cancer. BMC Cancer 10: 203
22. Nielsen HJ, Brunner N, Jorgensen LN, Olsen J, Rahr HB, Thygesen K, Hoyer U, Laurberg S, Stieber P, Blankenstein MA, Davis G, Dowell BL, Christensen IJ (2011) Plasma TIMP-1 and CEA in detection of primary colorectal cancer: a prospective, population based study of 4509 high-risk individuals. Scand J Gastroenterol 46: 60-69
23. Nikiteas NI, Tzanakis N, Gazouli M, Rallis G, Daniilidis K, Theodoropoulos G, Kostakis A, Peros G (2005) Serum IL-6, TNFalpha and CRP levels in Greek colorectal cancer patients: prognostic implications. World J Gastroenterol 11: 1639-1643 (Pubitemid 40520804)
24. Park DI, Ryu S, Kim YH, Lee SH, Lee CK, Eun CS, Han DS (2010) Comparison of guaiac-based and quantitative immunochemical fecal occult blood testing in a population at average risk undergoing colorectal cancer screening. Am J Gastroenterol 105: 2017-2025
25. Shimwell NJ, Wei W, Wilson S, Wakelam MJ, Ismail T, Iqbal T, Johnson PJ, Martin A, Ward DG (2010) Assessment of novel combinations of biomarkers for the detection of colorectal cancer. Cancer Biomark 7: 123-132
26. Tao S, Hundt S, Haug U, Brenner H (2011) Sensitivity estimates of blood-based tests for colorectal cancer detection: impact of overrepresentation of advanced stage disease. Am J Gastroenterol 106: 242-253
27. van Rossum LG, van Rijn AF, Laheij RJ, van Oijen MG, Fockens P, van Krieken HH, Verbeek AL, Jansen JB, Dekker E (2008) Random comparison of guaiac and immunochemical fecal occult blood tests for colorectal cancer in a screening population. Gastroenterology 135: 82-90 (Pubitemid 351899018)
28. Wild N, Andres H, Rollinger W, Krause F, Dilba P, Tacke M, Karl J (2010) A combination of serum markers for the early detection of colorectal cancer. Clin Cancer Res 16: 6111-6121